MedTrace Logo

Melflufen for Elderly Patients With Relapsed Myeloma

NCT06682637 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-04-01

No results posted yet for this study

Summary

This is a pilot study aimed to evaluate the efficacy and tolerability of melflufen plus dexamethasone in elderly patients at second relapse.

Thirty elderly patients at second or subsequent relapse.

Conditions

  • Relapse Multiple Myeloma

Interventions

DRUG

Melflufen

Pepaxti 20 mg powder for concentrate for solution for infusion

DRUG

Dexamethasone

SOLDESAM 8 mg/2 ml solution for injection SOLDESAM 0.2% oral drops, solution

Sponsors & Collaborators

  • Fondazione EMN Italy Onlus

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-26
Primary Completion
2025-03-26
Completion
2025-03-26

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06682637 on ClinicalTrials.gov